Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPS8s
- Development stage
- Preclinical
- Lead developer
- National Institute of Pharmaceutical Education and Research, Ahmedabad
01
Overview
CPS8s: sourced facts only. name: "Enzymatic verification by indirect cell free lactate dehydrogenase-coupled enzyme assay further established that CPS8s activates PKM2 activity." [PMID:42372628]; target: "Enzymatic verification by indirect cell free lactate dehydrogenase-coupled enzyme assay further established that CPS8s activates PKM2 activity." [PMID:42372628]; developer: "Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat 382355, India." [PMID:42372628]; stage: "Among 20 synthesized molecules, CPS8s emerged as an early-stage lead candidate, demonstrating significant cytotoxicity (A2780 IC50: 36.63 ± 0.13 μM) with 3-fold selectivity in HEK293T cells." [PMID:42372628]
02
Targets
PKM2 (Pyruvate kinase M2 isoform)
Beyond the preview
Go deeper on CPS8s.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPS8s.